PURPOSE: The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma. METHODS: Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression (%) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures. RESULTS: The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95% confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95% CI = 0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95% CI = 0.59 to 0.97). CONCLUSIONS: To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.
PURPOSE: The purpose of our study is to develop and validate a model to predict visual field (VF) outcomes in patients with treated glaucoma. METHODS: Data from 587 eyes with treated glaucoma evaluated in a cohort were used to develop two equations to predict VF outcomes, one estimating the risk of progression (%) and another estimating the global rate of VF sensitivity change (decibels [dB]/year). These equations, which included variables associated with VF progression in a multivariable model, then were tested in another cohort (n = 62 eyes) followed for at least 4 years. Agreement, discrimination, and calibration of the model in the validation sample were assessed as main outcome measures. RESULTS: The mean difference between observed and predicted global rates of sensitivity change was 0.13 dB/year (95% confidence interval [CI] = 0.06 to 0.18 dB/year) and the mean difference between observed and predicted final VF mean deviation (MD) values was 0.37 dB (95% CI = 0.00 to 0.75 dB). The predictive model had moderate discriminative ability to estimate VF progression in the independent sample (c-index of 0.78, 95% CI = 0.59 to 0.97). CONCLUSIONS: To our knowledge, this is the first attempt to generate and validate a risk model for patients with treated glaucoma. The prediction model showed moderate accuracy in estimating future VF outcomes in an independent glaucoma population, and may be useful for the objective assessment of risk of progressive VF loss.
Authors: Felipe A Medeiros; Pamela A Sample; Linda M Zangwill; Christopher Bowd; Makoto Aihara; Robert N Weinreb Journal: Am J Ophthalmol Date: 2003-11 Impact factor: 5.258
Authors: Felipe A Medeiros; Alexandre Pinheiro; Frederico C Moura; Bruno C Leal; Remo Susanna Journal: J Ocul Pharmacol Ther Date: 2002-12 Impact factor: 2.671
Authors: B C Chauhan; D F Garway-Heath; F J Goñi; L Rossetti; B Bengtsson; A C Viswanathan; A Heijl Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: Xinbo Zhang; Richard K Parrish; David S Greenfield; Brian A Francis; Rohit Varma; Joel S Schuman; Ou Tan; David Huang Journal: Am J Ophthalmol Date: 2019-02-20 Impact factor: 5.258
Authors: Brian C Stagg; Joshua D Stein; Felipe A Medeiros; Barbara Wirostko; Alan Crandall; M Elizabeth Hartnett; Mollie Cummins; Alan Morris; Rachel Hess; Kensaku Kawamoto Journal: Ophthalmol Glaucoma Date: 2020-08-15
Authors: Sally L Baxter; Bharanidharan Radha Saseendrakumar; Paulina Paul; Jihoon Kim; Luca Bonomi; Tsung-Ting Kuo; Roxana Loperena; Francis Ratsimbazafy; Eric Boerwinkle; Mine Cicek; Cheryl R Clark; Elizabeth Cohn; Kelly Gebo; Kelsey Mayo; Stephen Mockrin; Sheri D Schully; Andrea Ramirez; Lucila Ohno-Machado Journal: Am J Ophthalmol Date: 2021-01-23 Impact factor: 5.488
Authors: Joel S Schuman; Maria De Los Angeles Ramos Cadena; Rebecca McGee; Lama A Al-Aswad; Felipe A Medeiros Journal: Ophthalmol Glaucoma Date: 2021-12-22
Authors: Kwanghyun Lee; Bo Yi Kim; Gong Je Seong; Chan Yun Kim; Hyoung Won Bae; Sang Yeop Lee Journal: J Clin Med Date: 2021-05-29 Impact factor: 4.241